Novartis
Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data
September 17, 2020Research and Development Novartis, Tafinlar, mekinist, melanoma
Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …
Novartis’ Xolair scores European approval to treat chronic rhinosinusitis with nasal polyps
August 6, 2020Sales and Marketing Novartis, Xolair, rhinosinusitis
Novartis has snapped up approval from the European Commission for its anti-immunoglobulin E (IgE) antibody therapy Xolair (omalizumab) for the …
Novartis’ CAR T therapy Kymriah nails main goal in follicular lymphoma
August 4, 2020Manufacturing and Production, Research and Development CAR-T therapy, Cancer, Kymriah, Novartis, car t therapy
Novartis is celebrating the success of its one-time CAR T therapy Kymriah (tisagenlecleucel) in patients with relapsed or refractory (r/r) …
Novartis’ Cosentyx gets European go-ahead in paediatric plaque psoriasis
August 3, 2020Sales and Marketing Cosentyx, Europe, Novartis, pharma, psoriasis
Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) has chalked up approval from the European Commission (EC) for the treatment of patients …
Novartis’ Piqray combo becomes first Europe-approved therapy for PIK3CA-mutated advanced breast cancer
July 29, 2020Research and Development, Sales and Marketing Europe, Novartis, Piqray, breast cancer, pharma
The European Commission (EC) has awarded its approval for Novartis’ Piqray (alpelisib) to be made available in combination with fulvestrant …
Novartis to provide ‘no-profit’ generics to low income countries to help combat COVID-19
July 16, 2020Business Services COVID-19, Novartis, coronavirus, hydroxychloroquine
The Sandoz division of Novartis will not make a profit on the 15 generics it is making available to developing …
Novartis agrees to pay $347 million to settle bribery allegations
June 26, 2020Medical Communications Greece, Novartis, bribery
Novartis and its former eye care unit Alcon have agreed to pay a combined $347 million to resolve allegations that …
NICE knocks back Novartis’ Mayzent in secondary progressive multiple sclerosis over data gaps
June 25, 2020Sales and Marketing Mayzent, NHS, NICE, Novartis
Novartis’ Mayzent (siponimod) has been unsuccessful in securing a recommendation from NICE for use on the NHS for the treatment …
Novartis’ Cosentyx hits primary goal in Phase 3 non-radiographic axial spondyloarthritis study
June 4, 2020Research and Development Cosentyx, Novartis, axial spondyloarthritis
New Phase 3 data has been released on the efficacy of Novartis’ interleukin (IL)-17A inhibitor Cosentyx (secukinumab), showing that the …
Novartis releases results of MS drug trials weeks ahead of FDA verdict
May 28, 2020Business Services MS, Novartis
Novartis has revealed clinical trial data from testing its anti-CD20 leukameia drug Arzerra (ofatumumab) in patients with multiple sclerosis (MS). …
FDA approval for Tabrecta in metastatic non-small cell lung cancer with METex14
May 7, 2020Sales and Marketing Incyte, Novartis, Tabrecta, pharma
The FDA has awarded marketing authorisation to Novartis for the Oral MET inhibitor Tabrecta (capmatinib) for the first-line treatment of metastatic non-small …
EU approval for Novartis’ Cosentyx in active non-radiographic axial spondyloarthritis
April 29, 2020Research and Development, Sales and Marketing Cosentyx, EU, Novartis, axial spondyloarthritis, pharma
Novartis has revealed that the European Commission has moved to approve Cosentyx (secukinumab) for the treatment of active non-radiographic axial …
Novartis’ Jakavi Phase 3 trial is first of its kind to hit main goal in steroid-refractory acute graft-versus-host disease
April 23, 2020Research and Development Jakavi, Novartis, pharrma
Novartis has revealed impactful new Phase 3 data for its therapy Jakavi (ruxolitinib) in the treatment of patients with steroid-refractory …
Five-year data supports early treatment with Novartis’ Mayzent in secondary progressive multiple sclerosis
April 21, 2020Manufacturing and Production, Research and Development Mayzent, Novartis, pharma
Novartis has pulled back the curtain on five-year data from an extension trial for its sphingosine 1-phosphate receptor modulator Mayzent …
Steven T Gill returns to Alimera as VP, Thought Leader Engagement
April 3, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alimera Sciences, Novartis, pharma
Ophthalmology specialist Alimera Sciences has announced that Steven T Gill is to return to the company in the newly created …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
